Matthew W Boudreau
Overview
Explore the profile of Matthew W Boudreau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
199
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mulligan M, Boudreau M, Bouwens B, Lee Y, Carrell H, Zhu J, et al.
ACS Cent Sci
. 2025 Mar;
11(2):228-238.
PMID: 40028352
Patients with estrogen receptor α positive (ERα+) breast cancer typically undergo surgical resection, followed by 5-10 years of treatment with adjuvant endocrine therapy. This prolonged intervention is associated with a...
2.
Wang J, Su X, Jiang L, Boudreau M, Chatkewitz L, Kilgore J, et al.
Cancers (Basel)
. 2023 Dec;
15(24).
PMID: 38136388
Lung and breast cancers rank as two of the most common and lethal tumors, accounting for a substantial number of cancer-related deaths worldwide. While the past two decades have witnessed...
3.
Jiang L, Liu Y, Tumbath S, Boudreau M, Chatkewitz L, Wang J, et al.
Antioxid Redox Signal
. 2023 Nov;
41(1-3):74-92.
PMID: 37950707
Pancreatic cancer is among the top five leading causes of cancer-related deaths worldwide, with poor overall survival rates. Current therapies for pancreatic cancer lack tumor specificity, resulting in harmful effects...
4.
Boudreau M, Tonogai E, Schane C, Xi M, Fischer J, Vijayakumar J, et al.
Melanoma Res
. 2023 Sep;
33(6):514-524.
PMID: 37738028
The treatment of metastatic uveal melanoma remains a major clinical challenge. Procaspase-3, a proapoptotic protein and precursor to the key apoptotic executioner caspase-3, is overexpressed in a wide range of...
5.
Ferrins L, Olson M, Haranahalli K, Grenier-Davies M, Boudreau M, Matagne B, et al.
ACS Med Chem Lett
. 2023 Sep;
14(9):1129-1130.
PMID: 37736173
No abstract available.
6.
Ferrins L, Olson M, Haranahalli K, Grenier-Davies M, Boudreau M, Matagne B, et al.
J Med Chem
. 2023 Aug;
66(17):11591-11592.
PMID: 37642578
No abstract available.
7.
Ghosh S, Yang R, Duraki D, Zhu J, Kim J, Jabeen M, et al.
Cancer Res
. 2023 Jul;
83(18):3115-3130.
PMID: 37522838
Significance: A genome-wide CRISPR screen reveals a pivotal role for TRPM4 in cell death and immune activation following treatment with diverse necrosis-inducing anticancer therapies, which could facilitate development of necrosis-based...
8.
Boudreau M, Hergenrother P
RSC Med Chem
. 2022 Jul;
13(6):711-725.
PMID: 35814932
Development of targeted anticancer modalities has prompted a new era in cancer treatment that is notably different from the age of radical surgery and highly toxic chemotherapy. Behind each effective...
9.
Ferrins L, Araujo E, Boudreau M, Grenier-Davies M, Haranahalli K, Journigan V, et al.
J Med Chem
. 2022 Apr;
65(9):6353-6355.
PMID: 35467872
The Young Medicinal Chemists Committee (YMCC) is a part of the larger ACS Division of Medicinal Chemistry (MEDI) and was formed to ensure that MEDI meets the needs of medicinal...
10.
Boudreau M, Mulligan M, Shapiro D, Fan T, Hergenrother P
J Med Chem
. 2022 Jan;
65(5):3894-3912.
PMID: 35080871
Approximately 75% of breast cancers are estrogen receptor alpha-positive (ERα+), and targeting ERα directly with ERα antagonists/degraders or indirectly with aromatase inhibitors is a successful therapeutic strategy. However, such treatments...